Histogenics, which is developing a tissue implant to repair knee cartilage using regenerative medicine, raised $65 million by offering 5.9 million shares at $11, well below the $13 to $15 range. Histogenics will list on the NASDAQ under the symbol HSGX. Cowen & Company, Needham & Co. and Canaccord Genuity acted as joint bookrunners on the deal.
